We examined the safety and efficacy of controlled-release basic fibroblast growth factor (b-FGF) for peripheral artery disease (PAD), compared with autologous bone marrow mononuclear cell implantation (BMCI).
Background:
We recently developed a b-FGF-incorporated biodegradable hydrogel that enables slow-releasing drug delivery system.
Methods:
PAD patients were divided into a b-FGF group (n=10) and BMCI group (n=15). Injection of gelatin hydrogel containing 600 μg b-FGF or BMCI (0.4–5.1×1010 cell) was performed. Visual analog pain scale (VAS), 99mtechnetium-tetrofosmin (Tc-TF) scintigraphy, transcutaneous oxygen tension (TcPO2), and ankle-brachial index (ABI) were evaluated before and 4 weeks after each treatment, and 2-year prognosis was determined.
Results:
VAS (b-FGF 67±15 to 4±5, p<0.01, BMCI 67±42 to 5±9 mm, p<0.01) and TcPO2 (b-FGF 16±14 to 47±17, p<0.01, BMCI 13±13 to 37±21 mmHg, p<0.01) were significantly improved in both groups. Tc-TF and ABI were not changed. Prognosis was similar between the groups (b-FGF 91%, BMCI 80%, NS).
Conclusion:
Controlled-release b-FGF is as safe as BMCI, and its efficacy appears to be comparable. Thus, this therapy may be an alternative to BMCI.
Get full access to this article
View all access options for this article.
References
1.
CarmelietP.Angiogenesis in health and disease. Nat Med, 9:653. 2003.
2.
FolkmanJ.Angiogenesis: an organizing principle for drug discovery?Nat Rev Drug Discov, 6:273. 2007.
3.
MorenoP.R., SanzJ., FusterV.Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol, 53:2315. 2009.
4.
AlpertJ.S., LarsenO.A., LassenN.A.Exercise and intermittent claudication. Blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation, 39:353. 1969.
5.
KutrykM.J., StewartD.J.Angiogenesis of the heart. Microsc Res Tech, 60:138. 2003.
6.
LundgrenF., DahllofA.G., LundholmK., ScherstenT., VolkmannR.Intermittent claudication—surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann Surg, 209:346. 1989.
7.
NagyJ.A., DvorakA.M., DvorakH.F.VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med, 13:169. 2003.
SimonsM., WareJ.A.Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov, 2:863. 2003.
10.
KamihataH., MatsubaraH., NishiueT.et al.Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation, 104:1046. 2001.
11.
UemuraR., XuM., AhmadN., AshrafM.Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res, 98:1414. 2006.
12.
TatenoK., MinaminoT., TokoH.et al.Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res, 98:1194. 2006.
MiyamotoM., YasutakeM., TakanoH.et al.Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant, 13:429. 2004.
15.
KawanakaH., TakagiG., MiyamotoM.et al.Therapeutic angiogenesis by controlled-release fibroblast growth factor in a patient with Churg-Strauss syndrome complicated by an intractable ischemic leg ulcer. Am J Med Sci, 338:341. 2009.
16.
MaruiA., TabataY., KojimaS.et al.A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Circ J, 71:1181. 2007.
17.
TabataY., IkadaY.Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials, 20:2169. 1999.
LahamR.J., SellkeF.W., EdelmanE.R.et al.Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation, 100:1865. 1999.
20.
SchumacherB., PecherP., von SpechtB.U., StegmannT.Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation, 97:645. 1998.
21.
SchumacherB., StegmannT., PecherP.The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg (Torino), 39:783. 1998.
22.
LedermanR.J., MendelsohnF.O., AndersonR.D.et al.Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet, 359:2053. 2002.
23.
LazarousD.F., UngerE.F., EpsteinS.E.et al.Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol, 36:1239. 2000.
24.
FloegeJ., HudkinsK.L., EitnerF.et al.Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor-1 in adult human kidney. Kidney Int, 56:883. 1999.
25.
FloegeJ., BurgM., HugoC.et al.Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol, 9:792. 1998.
26.
FloegeJ., KrizW., SchulzeM.et al.Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest, 96:2809. 1995.
27.
FranckiA., UciechowskiP., FloegeJ., von der OheJ., ReschK., RadekeH.H.Autocrine growth regulation of human glomerular mesangial cells is primarily mediated by basic fibroblast growth factor. Am J Pathol, 147:1372. 1995.
28.
CooperL.T.Jr., HiattW.R., CreagerM.A.et al.Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med, 6:235. 2001.
29.
TabataY., MiyaoM., YamamotoM., IkadaY.Vascularization into a porous sponge by sustained release of basic fibroblast growth factor. J Biomater Sci Polym Ed, 10:957. 1999.
HashimotoT., KoyamaH., MiyataT.et al.Selective and sustained delivery of basic fibroblast growth factor (bFGF) for treatment of peripheral arterial disease: results of a phase I trial. Eur J Vasc Endovasc Surg, 38:71. 2009.
32.
TakeharaN., TsutsumiY., TateishiK.et al.Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol, 52:1858. 2008.
